Category: autoimmune disease
The latest start-up to emerge from the Roivant stable is named Priovant Therapeutics, and has been formed to develop a JAK1/TYK2 inhibitor originated by Pfizer as a treatment for autoimmune diseases. The drug – called brepocitinib – is the centrepiece of the new biotech’s R&D pipeline and is already a pair of pivotal trials in […]
AbbVie and Cugene have teamed up to research autoimmune diseases and cancer in an exclusive worldwide agreement. The Chicago-based pharma firm, AbbVie, received the option to license worldwide rights to Cugene’s CUG252 – a clinical-stage and potential best-in-class Treg-selective IL-2 mutein. It’s hoped that adding this drug to its portfolio will further boost AbbVie’s commitment […]
UCB has the positive result it was hoping for in its phase 3 trial of anti-neonatal FC receptor (FcRn) antibody rozanolixizumab for autoimmune disease generalised myasthenia gravis (gMG), setting up regulatory filings next year. The MycarinG study met its primary endpoint, demonstrating a “statistically significant and clinically meaningful” improvement from baseline in the myasthenia gravis-activities […]
Shots: Genovis to receive up front for an exclusive license to Xork & is eligible to receive development & sales-based milestones along with royalties on sales globally & holds the rights for research, preclinical, diagnostic & other non-therapeutic applications of Xork The collaboration will utilize Genovis’ IgG protease, IdeXork (Xork & Selecta’s ImmTOR platform for […]
ChemoCentryx has claimed FDA approval for its avacopan drug for a rare autoimmune disease, becoming the first orally-active drug that targets the complement C5 receptor. Avacopan will be launched as Tavneos in the coming weeks as a treatment for two forms of ANCA vasculitis – granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) – in […]
Eli Lilly and Incyte have another rival in the rear-view mirror for Olumiant in alopecia areata after Pfizer reported that its ritlecitinib improved scalp hair regrowth in a late-stage trial. In the phase 2b/3 ALLEGRO trial, JAK inhibitor ritlecitinib hit its primary objective of improving the area of scalp covered by hair in people with […]
Calliditas Therapeutics could have its first product on the market in the US this autumn, as the FDA has now started a priority review of Nefecon for rare disease primary IgA nephropathy (IgAN). The Swedish biotech says the IUS regulator has set an action date of 15 September for its review of Nefecon, a novel […]
Calliditas Therapeutics is on course to launch its first product, Nefecon for rare disease primary IgA nephropathy (IgAN), in the first half of 2022 after getting the green light for an accelerated review by the EMA. The Swedish biotech is planning to file Nefecon for approval in the second quarter to the EU regulator, which […]
Merck & Co/MSD has agreed to buy Pandion for $1.85 billion, bolting on a pipeline of drugs for autoimmune and other immunological disorders headed by interleukin-2 (IL-2) based therapy PT-101. The $60 per share is a handsome, more than 100% premium on Pandion’s closing share price yesterday, and gives Merck a foothold in the hot […]
New Models of Care in the Post-Covid Healthcare World Observations on models of care in a post-COVID world from HLTH VRTL 2020 with comments on applicability to autoimmune conditions. The Doctor Weighs In
Dealing with a Rare Eye Disease in the Midst of COVID19 After being diagnosed with a rare eye disease, a doctor learns the best treatment is immunosuppression-a risky choice in the midst of COVID19 The Doctor Weighs In
The drugmaker emphasized the full global rights it would acquire to Momenta’s lead asset, nipocalimab, which it is developing for several autoantibody-driven diseases and that in certain indications could have peak sales of more than $1 billion.
While there had been some risks to filgotinib’s approval cited before, analysts expressed surprise at the decision, with one writing it would likely delay approval by at least a year. Shares of both companies fell sharply on the news.
The agency approved Enspryng for the disease, which is often misdiagnosed as multiple sclerosis and can cause blindness, muscle weakness and paralysis.